GET DAILY SIGNALSAcadia Healthcare (ACHC) Posts +5.1% Revenue Growth in Q3 and Lifts 2026 Outlook
Key Takeaways
- Acadia Healthcare reported third quarter 2026 revenue of $895.3 million, up 5.1% year over year and above the consensus estimate of roughly $877.8 million.
- Adjusted diluted earnings per share (EPS) came in at $0.60, exceeding the analyst consensus of about $0.46, though it declined from $0.72 in the prior-year quarter.
- Reported (GAAP) net income attributable to Acadia was $34.5 million, or $0.38 per diluted share, compared with $36.2 million, or $0.40 per diluted share, a year earlier.
- The company raised its full-year 2026 guidance, now projecting revenue of $3.44 billion to $3.46 billion and adjusted EPS of $1.70 to $1.80.
- Results reflected continued volume growth in the acute services segment alongside ongoing cost and payer-authorization pressures.
Earnings Context and Why It Matters
Acadia Healthcare Company, Inc. (ACHC) operates a network of inpatient psychiatric facilities, specialty treatment centers, and comprehensive treatment centers across the United States and Puerto Rico. Its quarterly results draw attention because behavioral health demand stays structurally solid, even as the company manages higher labor costs, regulatory scrutiny, and payer authorization challenges. The third quarter ended September 30, 2026, also offers a checkpoint on management’s restructuring efforts and the ramp-up of newer facilities toward profitability. With the company raising full-year guidance, investors are evaluating whether better operational execution can support sustained earnings growth.
Reported Results
Acadia Healthcare announced its third quarter 2026 results on November 4, 2026, for the period ended September 30, 2026. Revenue reached $895.3 million, a 5.1% increase from the prior-year quarter and ahead of the consensus estimate of approximately $877.8 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On a reported (GAAP) basis, net income attributable to Acadia was $34.5 million, or $0.38 per diluted share, down from $36.2 million, or $0.40 per diluted share, in the same period last year. Adjusted net income attributable to Acadia was $54.6 million, or $0.60 per diluted share, compared with $64.8 million, or $0.72 per diluted share, a year earlier. Adjusted EPS of $0.60 beat the consensus estimate of roughly $0.46.
Management also raised its full-year 2026 outlook, lifting the revenue range to $3.44 billion to $3.46 billion and the adjusted EPS range to $1.70 to $1.80. The updated revenue midpoint of about $3.45 billion sits modestly above the prior consensus, while the adjusted EPS midpoint of $1.75 reflects a meaningful step up from earlier guidance.
Market Reaction and Investor Sentiment
Sentiment heading into the report was cautious, reflecting concerns about cost inflation, regulatory pressure, and slower-than-expected facility ramps. The combination of a revenue beat and higher full-year guidance appeared to offer a positive catalyst, with early post-earnings indications pointing toward a favorable market response. Investors weighed the strength of top-line growth and the guidance increase against the year-over-year decline in adjusted EPS, which highlighted ongoing margin pressures. The distinction between reported (GAAP) EPS of $0.38 and adjusted EPS of $0.60 also underscored the importance of separating one-time or non-operating items from core performance when interpreting the quarter.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching several factors tied to the company’s revised guidance. The raised adjusted EPS range of $1.70 to $1.80 signals management’s confidence in operational improvements, but sustaining that momentum will depend on disciplined cost management and the continued ramp of recently opened beds.
Labor costs remain a central variable. Behavioral healthcare is labor-intensive, and wage inflation or staffing shortages could pressure margins even as patient volumes grow. Equally important is the pace of new facility openings and how quickly those facilities reach target occupancy, since younger facilities typically weigh on near-term profitability before contributing earnings.
Payer dynamics are another area to monitor. Authorization friction and reimbursement trends can influence both revenue and the timing of cash collections. The company has also faced regulatory scrutiny, so any developments on that front could shape investor sentiment. From what I see, the company’s adjusted EBITDA trajectory will be a key gauge of underlying profitability, and I’m watching this closely.
Exploring AI-Powered Research Tools
In my own analysis, I often rely on Tickeron’s AI Screener to quickly filter stocks by industry, technical patterns, and performance metrics. It helps surface comparable names and monitor sector momentum without manual effort, which proves useful when tracking developments at companies like ACHC.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACHC's RSI Indicator leaves overbought zone
The 10-day RSI Indicator for ACHC moved out of overbought territory on October 15, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 22 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACHC turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 33 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 66%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
ACHC broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 63 cases where ACHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ACHC as a result. In 69 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
ACHC moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ACHC crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +4.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACHC advanced for three days, in 192 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 120 of 187 cases where ACHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ACHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.517) is normal, around the industry mean (204.059). P/E Ratio (-2.599) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (0.758) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of a network of behavioral health centers
Industry HospitalNursingManagement
Advertisement